Related by context. All words. (Click for frequent words.) 77 carboplatin paclitaxel 74 gemcitabine Gemzar 73 5-FU/LV 73 platinum refractory 73 gemcitabine carboplatin 72 melphalan prednisone 72 relapsed ovarian cancer 71 pegylated liposomal doxorubicin 71 chemoradiotherapy 71 Doxil ® 71 estramustine 71 vinorelbine 70 plus gemcitabine 70 fluoropyrimidine 70 doublet chemotherapy 70 taxane chemotherapy 70 docetaxel chemotherapy 70 debulking surgery 70 FOLFIRI 70 Pemetrexed 70 5 FU leucovorin 70 postoperative chemotherapy 70 cisplatin gemcitabine 70 Irinotecan 69 plus prednisone 69 gemcitabine cisplatin 69 dacarbazine 69 adriamycin 69 cisplatin vinorelbine 69 CHOP chemotherapy 69 recurrent NSCLC 69 5 fluorouracil leucovorin 69 FOLFOX6 69 mitomycin 69 FOLFOX4 69 recurrent metastatic 69 doxorubicin cyclophosphamide 69 Fludara 69 resistant ovarian cancer 69 taxotere 69 concurrent chemoradiation 69 sorafenib Nexavar 69 neoadjuvant 69 5FU 68 FOLFOX regimen 68 lopinavir r 68 irinotecan doxorubicin oxaliplatin paclitaxel 68 ribavirin RBV 68 metastatic renal cell carcinoma 68 Amrubicin 68 oblimersen 68 ritonavir boosted 68 chemotherapy cisplatin 68 daunorubicin 68 DOXIL 68 Erlotinib 68 gemcitabine chemotherapy 68 Folfox 68 epirubicin cyclophosphamide 67 docetaxel 67 capecitabine 67 Peg IFN 67 cisplatin carboplatin 67 interferon alfa 2a 67 pegylated interferon alfa 2b 67 Camptosar ® 67 Taxotere ® 67 Gemcitabine 67 fallopian tube carcinoma 67 chemotherapy docetaxel 67 sorafenib Nexavar ® 67 evaluating tivozanib 67 paclitaxel Taxol ® 67 docetaxel Taxotere 67 BEACOPP 67 bevacizumab Avastin ® 67 Taxotere R 67 Platinol 67 chlorambucil 67 Platinol ® cisplatin 67 refractory ovarian cancer 67 bendamustine 67 nab paclitaxel 67 bevacizumab Avastin 67 capecitabine Xeloda 67 trabectedin 67 paclitaxel Taxol 67 carboplatin 67 dacarbazine DTIC 67 mRCC 67 chemoradiation 67 stage IIIB 67 Capecitabine 67 interferon ribavirin 66 chemoradiation therapy 66 mitoxantrone plus 66 VELCADE melphalan 66 gemcitabine 66 metastatic malignant 66 goserelin 66 Sanofi Aventis Taxotere 66 low dose cytarabine 66 doxorubicin docetaxel 66 FOLFOX 66 adjuvant cisplatin 66 Epirubicin 66 docetaxel Taxotere R 66 FOLPI 66 docetaxel Taxotere ® 66 idarubicin 66 relapsed MM 66 cisplatin 66 metastatic castration resistant 66 metastatic CRC 66 peginterferon alpha 2a 66 alpha 2a 66 Alkeran 66 docetaxel prednisone 66 Panzem R NCD 66 FOLFIRI alone 66 stage IIIb IV 66 radiochemotherapy 66 XELOX 66 pegylated interferon alfa 2a 66 non squamous NSCLC 66 HER2 positive metastatic breast 66 chemo radiotherapy 66 refractory metastatic colorectal cancer 66 cyclophosphamide methotrexate 66 taxane therapy 66 comparator arm 66 sunitinib malate 66 FOLFOX6 chemotherapy regimen 66 infusional 5-FU/LV 66 alfa 2a 65 plus dexamethasone 65 oral clodronate 65 Fludarabine 65 mapatumumab 65 unresectable stage 65 flutamide 65 axitinib 65 nonmetastatic 65 Xeloda ® 65 neoadjuvant treatment 65 refractory multiple myeloma 65 cytotoxic chemotherapy 65 clodronate 65 cyclophosphamide doxorubicin vincristine 65 relapsed CLL 65 Platinol ® 65 mycophenolate mofetil 65 FUSILEV enhances 65 assessing T DM1 65 Gemzar ® 65 Flu Cy 65 cetuximab Erbitux ® 65 ABVD 65 fluorouracil 65 neurologic progression 65 iniparib 65 metastatic castrate resistant 65 unresectable 65 mg/m2 dose 65 trastuzumab Herceptin R 65 Cisplatin 65 zalutumumab 65 Hycamtin ® 65 pegylated liposomal doxorubicin PLD 65 oral ridaforolimus 65 Xelox 65 radiotherapy RT 65 abacavir lamivudine 65 lenalidomide dexamethasone 65 Taxol paclitaxel 65 adjuvant radiation 65 etoposide 65 locoregional recurrence 65 mitoxantrone chemotherapy 65 temozolomide TMZ 65 metastatic HRPC 65 dalteparin 65 temozolomide 65 advanced hepatocellular carcinoma 65 pemetrexed 65 paclitaxel Taxol R 65 liposomal doxorubicin 65 anthracyclines taxanes 65 Paraplatin ® 65 resectable 65 epirubicin 65 metastatic GIST 65 biliary tract cancer 65 urothelial bladder cancer 64 efavirenz EFV 64 Surgical resection 64 alkylating agent 64 metastatic colorectal carcinoma 64 prostate cancer HRPC 64 lenalidomide Revlimid R 64 5 fluorouracil 64 docetaxel cisplatin 64 NMIBC 64 Adjuvant chemotherapy 64 histologically confirmed 64 relapsed refractory multiple myeloma 64 aflibercept 64 cetuximab Erbitux 64 metastatic hormone refractory 64 ixabepilone 64 gefitinib Iressa 64 SCCHN 64 SPRYCEL ® 64 antiretroviral naïve 64 cisplatin chemotherapy 64 pertuzumab 64 external beam radiotherapy 64 tenofovir emtricitabine 64 demonstrated antitumor activity 64 PEG IFN 64 ZACTIMA 64 Paraplatin ® carboplatin 64 telaprevir dosed 64 topotecan 64 Novantrone 64 LHRH receptor positive 64 darunavir r 64 locoregional 64 paclitaxel poliglumex 64 recurrent ovarian cancer 64 Femara letrozole 64 dacarbazine chemotherapy 64 pegylated interferon alpha 64 irbesartan 64 Toxicities 64 neoadjuvant chemotherapy 64 fluorouracil leucovorin 64 Lenalidomide 64 anthracycline taxane 64 paclitaxel chemotherapy 64 sunitinib 64 Pegylated Interferon 64 CIMZIA TM certolizumab pegol 64 plus 5-FU/LV 64 biochemical relapse 64 boosted protease inhibitor 64 standard chemotherapy regimen 64 gemcitabine Gemzar ® 64 Cytoxan 64 ritonavir boosted atazanavir 64 metaglidasen 64 Pegasys plus Copegus 64 dose dexamethasone 64 CR nPR 64 erlotinib Tarceva ® 64 recurrent glioblastoma multiforme 64 tipranavir r 64 recurrent squamous cell carcinoma 63 cetuximab 63 gastrointestinal toxicities 63 Faslodex 63 aspirin clopidogrel 63 Taxotere docetaxel 63 Eli Lilly Gemzar 63 non resectable 63 peg IFN 63 placebo dexamethasone 63 Temsirolimus 63 CLL SLL 63 TACE 63 heavily pretreated patients 63 KRAS mutations occur 63 FluCAM 63 monotherapy 63 EGFR expressing 63 remission induction 63 Tarceva TM 63 temsirolimus 63 relapsed refractory 63 Proxinium TM 63 taxane 63 dasatinib Sprycel ® 63 oral diclofenac 63 anthracycline containing 63 cabazitaxel 63 peginterferon alfa 2b 63 Oxaliplatin 63 unfractionated heparin UFH 63 pain palliation 63 PegIFN 63 plus DOXIL 63 Halaven 63 EBRT 63 Combination therapy 63 Herceptin trastuzumab 63 HRPC 63 VNP#M 63 BRIM2 63 FASLODEX 63 EGFR mutation positive 63 metastatic malignant melanoma 63 Neoadjuvant 63 Taxotere chemotherapy 63 Cetuximab Erbitux 63 DCVax ® Brain 63 #mg BID [001] 63 #mg/m# [001] 63 Gliadel Wafer 63 metastatic CRPC 63 refractory metastatic 63 galiximab 63 irinotecan chemotherapy 63 antithymocyte globulin 63 thalidomide Thalomid 63 Hormone Refractory Prostate Cancer 63 TAXOTERE R 63 BR.# 63 pegfilgrastim 63 doxorubicin HCl liposome injection 63 #Gy 63 recurrent glioblastoma 63 decitabine 63 mitoxantrone 63 recurrent malignant glioma 63 TPV r 63 endoscopic remission 63 Topotecan 63 squamous histology 63 refractory AML 63 MAGE A3 ASCI 63 Trastuzumab 63 Peginterferon 63 sorafenib tablets 63 sunitinib Sutent 63 Gemzar gemcitabine 63 interferon alfa 2b 63 ALA PDT 63 metastatic colorectal 63 alpha interferons 63 azathioprine 63 paclitaxel cisplatin 63 PEGINTRON TM 63 prostate carcinoma 63 protease inhibitor PI 63 q#h 63 q8h 63 #mg QD [002] 63 metastatic RCC 63 Stage IIIb 63 EndoTAGTM 1 63 nilotinib Tasigna ® 63 drotrecogin alfa activated 63 adjuvant tamoxifen 63 Ixempra 63 5-fluorouracil/leucovorin 63 dexamethasone Decadron 63 adecatumumab 63 taxane resistant 63 cancer mCRC 63 CIMZIA TM 62 farletuzumab 62 metastatic pancreatic 62 ara C 62 interferon alfa 62 cyclophosphamide doxorubicin 62 4mg/kg 62 BCG refractory 62 temsirolimus Torisel ® 62 bortezomib Velcade 62 Fluorouracil 62 oral Hycamtin 62 mCRC patients 62 chemotherapeutic regimens 62 refractory chronic lymphocytic 62 neoadjuvant therapy 62 TTF Therapy 62 PegIFN RBV 62 fallopian tube cancers 62 5 Fluorouracil 62 intra arterial chemotherapy 62 cytotoxic therapy 62 ritonavir boosted lopinavir 62 evaluating Xcytrin 62 Peginterferon alfa 2b 62 evaluating bavituximab 62 ErbB2 positive 62 administered subcutaneously 62 pegylated interferon peg IFN 62 progression TTP 62 adjuvant therapy 62 phase IIb clinical 62 Elitek 62 cediranib 62 cetuximab Erbitux R 62 tamoxifen Nolvadex ® 62 preoperative chemotherapy 62 recurrent GBM 62 Copegus ribavirin 62 ELOXATIN 62 Telcyta 62 KRAS wild 62 Fulvestrant 62 ® lenalidomide 62 taxane refractory 62 TAXOTERE ® 62 Arimidex anastrozole 62 tumor xenograft models 62 Aptivus ® 62 ER CHOP 62 active comparator 62 CAELYX 62 relapsed SCLC 62 pancreatic adenocarcinoma 62 GW# [003] 62 epirubicin cisplatin 62 microwave hyperthermia 62 prednisone prednisolone 62 pegylated interferon alfa 62 abacavir Ziagen 62 ACTEMRA TM 62 chemotherapy FOLFOX 62 DOXIL ® 62 CCyR 62 salmeterol fluticasone 62 bosutinib 62 Tarceva erlotinib 62 beclomethasone dipropionate 62 Erbitux cetuximab 62 acute GvHD 62 AVASTIN 62 basal cell carcinoma BCC 62 dose cytarabine 62 CA4P 62 adalimumab Humira 62 adjuvant radiotherapy 62 metastatic SCCHN 62 refractory colorectal cancer 62 TEMODAL 62 surgical debulking 62 pT3 62 vincristine doxorubicin 62 ARB telmisartan 62 oxaliplatin Eloxatin 62 infusional 62 systemic ALCL 62 #mg q8h 62 Imprime PGG 62 Allovectin 7 ® 62 Hazard Ratio 62 Vidaza ® 62 Free Survival PFS 62 tamsulosin 62 dasatinib Sprycel 62 #mg BID [003] 62 Fludara ® 62 MGd 62 peginterferon alfa 2a 62 CANCIDAS 62 Velcade bortezomib 62 antiandrogen 62 PREZISTA r 62 adenoma recurrence 62 liposomal formulation 62 aromatase inhibitor AI 62 #mg/m# [002] 62 mg qd 62 DMARD 62 carboplatin chemotherapy 62 temozolomide Temodar 62 intravesical therapy 62 completely resected 62 vinca alkaloid 62 novel emulsion formulation 62 saline placebo 62 genotypic resistance 62 vandetanib 62 pomalidomide 62 mg BID 62 receptor tyrosine kinase inhibitor 62 telaprevir dosing 62 ceftazidime 62 ibandronate 62 trastuzumab Herceptin ® 62 immunomodulatory therapy 62 COMBIVIR 62 hypofractionated 62 chemotherapeutic regimen 62 PEG interferon 62 trans retinoic acid ATRA 61 IV NSCLC 61 metastatic squamous cell carcinoma 61 #mg QD [001] 61 achieved ACR# 61 ancrod 61 liposomal amphotericin B 61 chemotherapeutic drug 61 HuMax EGFr 61 Xeloda capecitabine 61 stage IIIB IV 61 Targretin capsules 61 evaluating satraplatin 61 biologic therapy 61 Bevacizumab Avastin 61 metastatic bladder 61 baseline LDH 61 Xanafide 61 relapsing multiple sclerosis 61 IFN alfa 61 pharmacologically active isomer 61 leukemia AML 61 oral rivaroxaban 61 mg m² 61 CLARITY study 61 3TC lamivudine Epivir 61 bevacizumab 61 papillary renal cell carcinoma 61 Aflibercept 61 bevacizumab Avastin R 61 adjuvant colon cancer 61 Nexavar sorafenib 61 radiation chemoradiation 61 gemtuzumab ozogamicin 61 amrubicin 61 advanced unresectable 61 metastatic carcinoma 61 generation purine nucleoside 61 metastatic androgen independent 61 hormone refractory prostate cancer 61 bortezomib Velcade R 61 CYT# potent vascular disrupting 61 Darusentan 61 overlapping toxicities 61 bacillus Calmette Guerin 61 biologic DMARD 61 LEXIVA r 61 levosimendan 61 Neulasta R 61 Cyclophosphamide 61 noninferior 61 rFSH 61 platelet inhibitor 61 lapatinib Tykerb 61 PSMA ADC 61 Patients Treated With 61 androgen independent 61 multicenter randomized placebo controlled 61 Allovectin 7 61 follicular lymphoma FL 61 conventional DMARDs 61 prostate cancer CRPC 61 luteinizing hormone releasing 61 novel VDA molecule 61 dextromethorphan quinidine 61 hormone refractory metastatic prostate 61 HGS ETR2 61 Etoposide 61 pamidronate 61 Hsp# Inhibitor 61 cyclophosphamide AC 61 chemotherapy gemcitabine 61 TO AVOID PREGNANCY WHILE 61 Hycamtin 61 Torisel 61 non squamous 61 Docetaxel 61 tipranavir 61 dose cohort 61 GP IIb IIIa inhibitors 61 custirsen 61 fluticasone propionate FP 61 Avastin Tarceva 61 Mitomycin C 61 infliximab monotherapy 61 zonisamide SR 61 ARIMIDEX 61 OPAXIO 61 erlotinib 61 lymphadenectomy 61 surgically resectable 61 standard chemotherapy regimens 61 pT2 61 Cloretazine ® 61 Nilotinib 61 oxaliplatin 61 oral allopurinol 61 IFN α 61 Ceplene/IL-2 61 refractory NSCLC 61 Dasatinib 61 rosuvastatin #mg 61 weekly subcutaneous injections 61 intermittent dosing 61 unresectable HCC 61 IIIa inhibitor 61 Telintra 61 oxycodone CR 61 PegIntron 61 Revlimid lenalidomide 61 ELACYT 61 humanised monoclonal antibody 61 azacitidine 61 Pegasys ® 61 pegylated interferons 61 zoledronic acid Zometa 61 neratinib 61 paclitaxel 61 castrate resistant 61 LPV r 61 viral kinetics 61 fludarabine cyclophosphamide 61 CPOP R 61 eribulin mesylate 61 TORISEL 61 BCIRG 61 Bevacizumab 61 huN# DM1 61 melphalan 61 adjuvant trastuzumab 61 glufosfamide 61 untreated multiple myeloma 61 TYKERB 61 Mitoxantrone 61 trials RCTs 61 anastrazole 61 pCR 61 Cloretazine 61 oral vancomycin 61 multicenter randomized controlled 61 xanthine oxidase inhibitor 61 Phase Ib clinical 61 Neulasta ® 61 fosbretabulin 61 MabCampath 61 interferon gamma 1b 61 superficial bladder cancer 61 β blockers 61 localized renal 61 prostate cancer mCRPC 61 relapsed multiple myeloma 61 cilengitide 61 Vicinium TM 61 Exemestane 61 clinically localized prostate 61 cytoreduction 61 BENICAR HCT 61 Aplidin 61 Ibritumomab Tiuxetan 61 Temodar ® 61 Pharmacokinetics PK 61 EFAPROXYN 61 androgen deprivation 61 APTIVUS r 61 8mg/kg 61 abiraterone acetate 61 mesalazine 61 radiation sensitizer 61 EURIDIS 61 Phase III randomized controlled 61 nonmetastatic prostate cancer 61 ß blockers 61 Targretin 61 imatinib Gleevec ® 61 tumors GIST 60 oral deforolimus 60 cyclophosphamide vincristine 60 refractory gastrointestinal stromal 60 miconazole Lauriad ® 60 pegylated interferon 60 intravesical 60 histone deacetylase HDAC inhibitor 60 colorectal adenoma 60 R sorafenib tablets 60 rituximab Rituxan 60 BARACLUDE ® 60 ORAL HYCAMTIN 60 ritonavir boosted protease inhibitor 60 teriflunomide 60 peg interferon 60 receiving highly emetogenic 60 NRTI 60 androgen ablation 60 PSA nadir 60 cytarabine daunorubicin 60 metastatic renal 60 peripheral sensory neuropathy 60 COPEGUS 60 trastuzumab DM1 60 metastatic colorectal cancer 60 antiangiogenic therapy 60 sargramostim 60 Caelyx 60 TELCYTA 60 dasatinib 60 SIR Spheres 60 combretastatin A4 phosphate CA4P 60 lumiliximab 60 prospectively defined 60 cytarabine 60 antimetabolite 60 prednisone VcMP 60 Adjuvant Treatment 60 stage IIIb 60 NSABP B 60 hepatic metastases 60 plus prednisone prednisolone 60 Taxol ® 60 alvespimycin 60 VcMP 60 corticosteroid dexamethasone 60 Camptosar ® irinotecan 60 Bezielle 60 sorafenib Nexavar R 60 eluting stent 60 azacytidine 60 Cimzia TM 60 Phase #b/#a clinical 60 nucleoside analog 60 resectable pancreatic cancer 60 Interferon alfa 60 hydroxymethyl coenzyme 60 Rituxan rituximab 60 chemotherapy regimens 60 iniparib BSI 60 regorafenib 60 Hodgkin lymphoma HL 60 investigational immunotherapy 60 ug dose 60 HER2 negative 60 Taxotere 60 prospective multicenter 60 Navelbine ® 60 mTOR inhibitor 60 cytoreductive nephrectomy 60 histologic subtype 60 Cloretazine R VNP#M 60 leuprorelin 60 sorafenib 60 irinotecan 60 AVONEX ® 60 docetaxel Injection Concentrate 60 Gefitinib 60 visceral metastases 60 EGFR expressing mCRC 60 #:# randomization 60 CIMZIA ™ 60 pegylated interferon alpha 2a 60 FOLFOX chemotherapy 60 histologies 60 trastuzumab 60 underwent surgical resection 60 Pegasys peginterferon alfa 2a 60 ribavirin therapy 60 Gleevec imatinib mesylate 60 BRAF inhibitor 60 severe neutropenia 60 microtubule inhibitor 60 naïve HCV 60 follicular NHL 60 cinacalcet 60 malignant pleural mesothelioma 60 DAPT 60 octreotide LAR 60 ABC/3TC 60 xenograft models 60 HGS# 60 everolimus eluting stents 60 Bosutinib 60 tipranavir ritonavir 60 evaluable 60 hypomethylating agents 60 anti angiogenic agents 60 EGFR TKI 60 median survivals 60 Vidaza azacitidine 60 colorectal cancer liver metastases 60 tacrolimus ointment 60 Roche Xeloda 60 mcg QD 60 paclitaxel eluting stents 60 nucleoside analogue 60 elotuzumab 60 Campath alemtuzumab 60 INCB# [003] 60 gastrointestinal stromal tumors 60 endometrial carcinoma 60 operable breast cancer 60 Phase #b/#a trial 60 castrate resistant prostate cancer 60 ZOLINZA 60 INTELENCE 60 hematologic toxicity 60 preoperative radiotherapy 60 evaluating picoplatin 60 haematologic 60 evaluating REVLIMID 60 Natalizumab 60 FEMALES SHOULD BE ADVISED 60 TELINTRA 60 CRp 60 panitumumab Vectibix 60 Decitabine 60 Sorafenib 60 volociximab 60 Pegylated Liposomal Doxorubicin 60 advanced NSCLC 60 celgosivir 60 DU #b 60 TMC# r 60 blind multicenter 60 forodesine 60 heavily pretreated 60 etanercept Enbrel 60 urothelial carcinoma 60 randomized multicentre 60 seliciclib 60 multicentre randomized 60 ONCASPAR 60 enzastaurin 60 6 mercaptopurine 60 gadobutrol 60 colorectal carcinoma 60 Ophena TM 60 unresectable locally advanced 60 inhibitor RG# 60 MDS AML 60 cytostatic 60 refractory indolent non 60 fondaparinux 60 oral chemotherapeutic agent 60 fludarabine 60 Phase #/#a trial 60 bone metastases 60 folinic acid 60 Helicobacter pylori eradication 60 intravenous bisphosphonates 60 nonsquamous 60 cyclophosphamide 60 Relapsed Refractory 60 CTEPH 60 gastrointestinal stromal tumors GIST 60 ongoing Phase 1b 60 Thal Dex 60 mcg kg 60 Randomized Phase II 60 care regimens CCR 60 Degarelix 60 clinicopathological features 60 lipid lowering agents 60 darunavir ritonavir 60 partial remissions 60 piperacillin tazobactam 60 visilizumab 60 TRANSFORMS 60 Trabectedin 60 vidofludimus 60 LHRH analogues 60 mycophenolic acid 60 Pegintron 60 raloxifene Evista 59 nonsmall cell lung cancer 59 TMP SMX 59 dose dose escalation 59 trastuzumab emtansine T DM1 59 metastatic gastric 59 REOLYSIN ® 59 uric acid lowering 59 plus ribavirin 59 FOLFIRINOX 59 APTIVUS R 59 sunitinib Sutent ® 59 AZT zidovudine Retrovir 59 TheraCIM h R3 59 neuropathy sparing 59 medically inoperable 59 bevacizumab Avastin Genentech 59 leucovorin 59 SVR# 59 Acute Coronary Syndromes ACS 59 μg dose 59 Radical prostatectomy 59 HBeAg negative 59 bendamustine ifosfamide 59 interferon α 59 Navelbine 59 HGS ETR1 59 Ophena 59 T1c 59 fluvastatin 59 BRCA deficient 59 iodixanol 59 denileukin diftitox 59 fosamprenavir 59 RhuDex TM 59 noninferiority 59 NSABP C 59 Randomized Phase 59 ALIMTA cisplatin 59 Carboplatin 59 letrozole Femara 59 caspofungin 59 NSCLC 59 apremilast 59 Voreloxin 59 potentially hepatotoxic 59 Interferon beta 59 Akt inhibitor 59 MetMAb 59 ibritumomab tiuxetan 59 YONDELIS 59 Pfizer Sutent 59 intravenous cyclophosphamide 59 Clolar ® 59 exemestane Aromasin 59 tesmilifene 59 exemestane 59 q#d 59 thienopyridine 59 prostate cancer AIPC 59 XYOTAX TM 59 ASCT 59 mg kg dose 59 gefitinib 59 Doxil 59 Randomised 59 diagnosed multiple myeloma 59 Median PFS 59 HCV RESPOND 2 59 symptomatic BPH 59 temsirolimus Torisel 59 IIIA NSCLC 59 lexidronam injection 59 virologic failure 59 Alocrest 59 pancreatic carcinoma 59 Omnitarg 59 tiuxetan 59 chemotherapy regimen 59 EOquin TM 59 Capesaris 59 thalidomide dexamethasone 59 adjuvant chemotherapy 59 atazanavir ritonavir 59 bortezomib 59 relapsing remitting MS RRMS 59 imatinib Gleevec 59 idraparinux 59 orally administered inhibitor 59 leukemia CLL 59 timolol 59 oral Xeloda 59 CR CRu 59 eplerenone 59 Combination REOLYSIN R 59 #.#g/day 59 Vectibix 59 OncoVEX GM CSF 59 SCH # 59 Paraplatin 59 Omacetaxine 59 IRX 2 59 cystectomy 59 sirolimus eluting stents 59 malignancy HCM 59 dose escalation clinical 59 median PFS 59 virus HCV protease inhibitor 59 Nexavar ® 59 CYP#D# inhibitor 59 AVOREN 59 baminercept 59 nilotinib 59 Pfizer Camptosar 59 HSP# inhibitor 59 dose regimens 59 eribulin 59 glycoprotein IIb IIIa inhibitor 59 ribavirin Copegus ® 59 HER2 + 59 nicardipine 59 moderately emetogenic 59 irinotecan cisplatin 59 non resectable metastatic 59 anthracycline chemotherapy 59 candesartan cilexetil 59 refractory CTCL 59 erlotinib Tarceva 59 invasive ductal 59 alefacept 59 Vinorelbine 59 imiquimod cream 59 interstitial brachytherapy 59 fluticasone salmeterol 59 mcg albinterferon alfa 2b 59 doxorubicin Adriamycin 59 sunitinib sorafenib 59 pediatric malignancies 59 bleomycin 59 tanespimycin 59 intralesional